Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2017 September;59(3) > Panminerva Medica 2017 September;59(3):269-73

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Panminerva Medica 2017 September;59(3):269-73

DOI: 10.23736/S0031-0808.16.03211-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Angiotensin receptor blockers and breast cancer risk: a meta-analysis

Yun-Feng QIAN , Wei-Guo XU, Jun WU

Department of Geriatrics, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China


PDF


INTRODUCTION: Some studies reported that angiotensin receptor blockers (ARBs) reduced the risk of breast cancer. However, other studies did not show similar results.
EVIDENCE ACQUISITION: The PubMed and EMBASE databases were searched. The strength of the association between ARBs and the risk of breast cancer was measured by odds ratio (OR) and 95% confidence interval (CI).
EVIDENCE SYNTHESIS: Eight eligible studies with 1,994,880 individuals were considered for this meta-analysis. ARBs was not associated with the risk of breast cancer (OR=0.93; 95% CI: 0.81-1.06; I2=86%). In the subgroup analysis of race, a significantly decreased breast cancer risk were observed in Asians (OR=0.62; 95% CI: 0.53-0.73; I2=0%). However, a significantly increased breast cancer risk were observed in Caucasians (OR=1.08; 95% CI: 1.02-1.13; I2=28%).
CONCLUSIONS: This study provided evidence that ARBs was associated with decreased breast cancer in Asians and increased risk of breast cancer in Caucasians.


KEY WORDS: Angiotensin receptor antagonists - Breast neoplasms - Meta-analysis

top of page